A novel palmitoylethanolamide formulation improves hyperalgesia and red cell instability in murine sickle cell disease
Year: 2026
Type: article
Abstract: 1. Oral, water-dispersible palmitoylethanolamide is rapidly bioavailable and improves hematological markers of sickle cell disease. 2. Oral palmitoylethanolamide reduces inflammation as well as chronic and acute hyperalgesia in sickle cell disease.
Institutions: University of California, Irvine, University of Minnesota
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,000
Funders: A.P. Giannini Foundation, University of California, National Institutes of Health, National Heart, Lung, and Blood Institute, National Cancer Institute, National Center for Complementary and Integrative Health, Center for Medicinal Cannabis Research, University of California, San Diego, Institute for Clinical and Translational Science, University of California, Irvine
OpenAlex ID: W7118186956